The Psychedelic Conversation Just Got Very Federal

This content is protected against AI scraping.

The Substance Abuse and Mental Health Services Administration (SAMHSA), a federal agency within the U.S. Department of Health and Human Services focused on mental health and substance use, is telling states to start preparing now for the possibility that psychedelic medicines could become FDA-approved treatments. A new report says research into substances like psilocybin and MDMA has accelerated dramatically after decades of being held back by their Schedule I status. While the agency says the evidence is still uneven, studies show potential for treating conditions including PTSD, depression, anxiety and substance use disorders. The FDA has already given “breakthrough therapy” status to several psychedelic treatments, and the federal government is increasingly pushing research forward.

The interesting part is that SAMHSA isn’t telling states to become psychedelic advocates—it’s telling them to start preparing now for the possibility that FDA-approved psychedelic therapies could arrive. States may eventually have to figure out everything from licensing and safety standards to Medicaid coverage for medications and the hours-long therapy sessions that can go with them. The report also points out a pretty obvious problem: people are already using psychedelics, regardless of whether governments have created a legal framework for them. The question is whether that use happens through regulated systems or underground markets. Federal law and state law could also end up colliding, much like they already do with cannabis.

This is a summary.
Please read the original article: States Should Start Planning Now For FDA Approval Of Psychedelics, Federal Report Says
Original article written by . Published on August 26, 2026 by Marijuana Moment.